Hemab Therapeutics (NASDAQ:COAG) Trading Up 10.5% – Still a Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) rose 10.5% on Friday . The stock traded as high as $30.63 and last traded at $30.63. 23,297 shares traded hands during trading, a decline of 91% from the average daily volume of 253,068 shares. The stock had previously closed at $27.72.

Analysts Set New Price Targets

COAG has been the subject of several recent analyst reports. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price for the company. Evercore initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Hemab Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $41.40.

Hemab Therapeutics Stock Performance

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Activity

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the purchase, the insider owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. The trade was a 0.96% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired a total of 2,970,541 shares of company stock valued at $55,459,603 over the last ninety days.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.